華康生物醫學：2025中期報告.pdf

1、2025INTERIM REPORT中期報告Huakang Biomedical Holdings Company Limited華 康 生 物 醫學 控股 有 限 公 司(incorporated in the Cayman Islands with limited liability)(於開曼群島註冊成立之有限公司)Stock Code 股份代號:8622 CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED(THE“STOCK EXCHANGE”)香港聯合交易所有限公司（聯交所）GEM之特色 GEM has b

2、een positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange.Prospective investors should be aware of the potential risks of investing in such companies and should make the decisio

3、n to invest only after due and careful consideration.Given that the companies listed on GEM are generally small and mid-sized companies,there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board of the Stock Exchange and n

4、o assurance is given that there will be a liquid market in the securities traded on GEM.Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this report(“Report”),make no representation as to its accuracy or completeness and expressly disclaim an

5、y liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of the Report.This Report,for which the directors(the“Directors”)of Huakang Biomedical Holdings Company Limited(the“Company”,and together with its subsidiaries,the“Group”,“we”or“our”)

6、collectively and individually accept full responsibility,includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of the Stock Exchange(the“GEM Listing Rules”)for the purpose of giving information with regard to the Group.The Directors,having made all reason